PositoAI
a positivity index
Home Explore Actions Flows Indices News Watchlist Compare PosiDemy Screeners Insights
PosiFunda · Fundamentals

Terminalcare Support Institute Inc.

Standard fundamentals

P/E, P/B, ROE, debt, growth and more (14)

Terminalcare Support Institute Inc. owes ¥0.75 for every ¥1 it owns. Net profit fell 35% in the year to Dec 2025, and shrank 20% a year on average over 3 years.

Compared with Healthcare companies in Japan · latest annual results Dec 2025.

P/E ratio

8.9

Investors pay ¥8.9 for every ¥1 of Terminalcare Support Institute Inc.'s yearly profit, lower than 92% of Healthcare companies in Japan.

P/B ratio

0.88

The share price is 0.88 times Terminalcare Support Institute Inc.'s book value per share, lower than 81% of Healthcare companies in Japan.

Market cap

¥1.3 B

The total market value of all of Terminalcare Support Institute Inc.'s shares at today's price (share price × number of shares), smaller than 98% of Healthcare companies in Japan. PosiCap size class: Nano Cap.

Net worth (book value)

¥1.5 B

What Terminalcare Support Institute Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).

Book value per share

¥963.10

Net worth divided by the number of shares. The share price of ¥845.00 is 0.9 times this, which is the P/B above.

Return on equity (ROE)

10.2%

Terminalcare Support Institute Inc. earned 10.2% on its shareholders' money over the last year, higher than 65% of Healthcare companies in Japan.

Owes vs Owns

0.75×

Terminalcare Support Institute Inc. owes ¥0.75 for every ¥1 it owns (moderate), higher than 89% of Healthcare companies in Japan.

Dividend yield

1.19%

Terminalcare Support Institute Inc. pays 1.19% of its share price as dividends a year, lower than 90% of dividend-paying Healthcare companies in Japan.

Revenue growth

+4%

Revenue rose 4% in the year to Dec 2025, and grew 6% a year on average over 3 years.

Profit growth

-35%

Net profit fell 35% in the year to Dec 2025, and shrank 20% a year on average over 3 years.

Profit margin

1.7%

Terminalcare Support Institute Inc. keeps ¥2 of every ¥100 of revenue as net profit.

Cash quality

3.5×

Cash from Terminalcare Support Institute Inc.'s business was 3.5× its reported profit in the year to Dec 2025 — its profit turned into cash.

Interest cover

0.9×

Terminalcare Support Institute Inc.'s operating profit covered its interest costs 0.9 times in the year to Dec 2025.

Cash vs debt

Net debt

Terminalcare Support Institute Inc. had ¥2.4 B more debt than cash (net debt) at Dec 2025.

Questions

What is Terminalcare Support Institute Inc.'s P/E ratio?

Investors pay ¥8.9 for every ¥1 of Terminalcare Support Institute Inc.'s yearly profit, lower than 92% of Healthcare companies in Japan.

How is P/B calculated on PositoAI?

P/B is market cap divided by net worth from the latest balance sheet. For Terminalcare Support Institute Inc.: ¥1.3 B ÷ ¥1.5 B (30 Jun 2026) = 0.9.

What is Terminalcare Support Institute Inc.'s return on equity?

Terminalcare Support Institute Inc. earned 10.2% on its shareholders' money over the last year, higher than 65% of Healthcare companies in Japan.

How much does Terminalcare Support Institute Inc. owe compared with what it owns?

Terminalcare Support Institute Inc. owes ¥0.75 for every ¥1 it owns (moderate), higher than 89% of Healthcare companies in Japan.

Does Terminalcare Support Institute Inc. pay a dividend?

Yes. Terminalcare Support Institute Inc. pays 1.19% of its share price as dividends a year, lower than 90% of dividend-paying Healthcare companies in Japan.

Is Terminalcare Support Institute Inc.'s revenue growing?

Revenue rose 4% in the year to Dec 2025, and grew 6% a year on average over 3 years.

Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.